| CPC A61K 9/1647 (2013.01) [A61K 9/0019 (2013.01); A61K 31/57 (2013.01)] | 13 Claims |

|
1. An injectable sustained-release formulation, comprising:
(a) microspheres comprising progesterone and a biodegradable composition comprising one or more poly(lactic-co-glycolic acid) copolymers (PLGA), and
(b) a diluent solution in which the microspheres are suspended wherein the one or more PLGA copolymers is a PLGA copolymer with a molar ratio of lactide to glycolide of about 50:50, about 75:25 or is a combination of PLGA copolymers with a molar ratio of lactide to glycolide of about 50:50 and 75:25 and a molecular weight in the range between 4 kD and 75 kD;
wherein the progesterone is present in an amount of between about 35% and about 50% by weight of the microspheres; and
the microspheres encapsulating the progesterone have a mean diameter of between about 50 μm and about 100 μm; and
wherein an in vitro release profile graph of the microspheres exhibits a linear correlation coefficient equal to or greater than 0.75 from a 0,0 time point to a 70% progesterone release point on the graph when the in vitro release profile is determined by placing approximately 20-25 mg of the microspheres in a container comprising about 200 mL of a release medium comprising a phosphate-buffered saline solution with 0.5% of sodium dodecyl sulfate, 0.02% sodium azide, and a pH of about 7.40 and placing the container with the microspheres and release medium in a 37° C. water bath shaking at a speed of about 90 RPM.
|